Advertisement

Substance Abuse Disorders

  • James W. Jefferson
  • John R. Marshall
Part of the Critical Issues in Psychiatry book series (CIPS)

Abstract

The fact that caffeine in the form of coffee, tea, cocoa, cola beverages, and over-the-counter medications is probably the most widely used psychoactive substance helps account for its neglect as the cause of a variety of psychiatric symptoms. Caffeine is such an integral part of our society that its use (and abuse) is not associated with the stigma attached to other substances of abuse such as alcohol, opioids, and barbiturates. Unlike even tobacco, the use of caffeine in children in the form of colas, cocoa, and chocolate is almost universally accepted.

Keywords

Antipsychotic Drug Substance Abuse Disorder Caffeine Content Psychiatric Drug Narcotic Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Änggård E, Jönsson L-E, Hogmark A-L, et al: Amphetamine metabolism in amphetamine psychosis. Clin Pharmacol Ther 14: 870–880, 1973.PubMedGoogle Scholar
  2. Angrist B, Sudilovsky A: Central nervous system stimulants: Historical aspects and clinical effects, in Iverson LL, Iverson SD, Snyder SH (eds): Handbook of Psychopharmacology. New York, Plenum Press, 1978, pp 99–165.Google Scholar
  3. Anonymous: Alcohol-drug interactions. FDA Drug Bull 9: 10–12, 1979.Google Scholar
  4. Beamish P, Kiloh LG: Psychoses due to amphetamine consumption. J Ment Sci 106: 337–343, 1960.PubMedGoogle Scholar
  5. Brecher EM: Licit and Illicit Drugs. Mount Vernon, New York, Consumers Union, 1972, pp 33–41.Google Scholar
  6. Buckman RW: Drug interactions and the practice of psychiatry. Current Concepts Psychiatry 2:1–12, January and April, 1976.Google Scholar
  7. Bunker ML, McWilliams M: Caffeine content of common beverages. JAm Dietetic Assoc 74: 28–32, 1979.Google Scholar
  8. Byck R: Drugs and the treatment of psychiatric disorders, in Goodman LS, Gilman A (eds): The Pharmacological Basis of Therapeutics. New York, Macmillan, 1975, pp 152–200.Google Scholar
  9. Cohen S: Amphetamine abuse. JAMA 231: 414–415, 1975.PubMedCrossRefGoogle Scholar
  10. Cohen S: Angel dust. JAMA 238: 515–516, 1977.PubMedCrossRefGoogle Scholar
  11. De Freitas B, Schwartz G: Effects of caffeine in chronic psychiatric patients. Am J Psychiatry 136: 1337–1338, 1979.PubMedGoogle Scholar
  12. Diagnostic and Statistical Manual of Mental Disorders, ed 3. Washington, American Psychiatric Association, 1980.Google Scholar
  13. Dreisbach RH, Pfeiffer C: Caffeine-withdrawal headache. J Lab Clin Med 28: 1212–1219, 1943.Google Scholar
  14. Garfield E: Should we kick the caffeine habit? Curr Contents 23:5–9, February 18, 1980.Google Scholar
  15. Gary NE, Saidi P: Methamphetamine intoxication, a speedy new treatment. Am JMed 64: 537–540, 1978.Google Scholar
  16. Gilbert RM, Marshman JA, Schwieder M, et al: Caffeine content of beverages as consumed. J Can Med Assoc 114: 205–208, 1976.Google Scholar
  17. Goldstein A, Kaizer S: Psychotropic effects of caffeine in man: III. A questionnaire survey of coffee drinking and its effects in a group of housewives. Clin Pharmacol Ther 10: 477–488, 1969.PubMedGoogle Scholar
  18. Goodwin DW: Alcoholic blackout and state-dependent learning. Fed Proc 33: 1833–1835, 1974.PubMedGoogle Scholar
  19. Greden JF: Anxiety or caffeinism: A diagnostic dilemma. Am J Psychiatry 131: 1089–1092, 1974.PubMedGoogle Scholar
  20. Greden JF, Fontaine P, Lubetsky M, et al: Anxiety and depression associated with caffeinism among psychiatric inpatients. Am J Psychiatry 135: 963–966, 1978.PubMedGoogle Scholar
  21. Greden JF, Victor BS, Fontaine P, et al: Caffeine-withdrawal headache: A clinical profile. Psychosomatics 21: 411–418, 1980.PubMedGoogle Scholar
  22. Griffith JD, Cavanaugh JH, Held J, et al: Experimental psychosis induced by the administration of d-amphetamine, in Costa E, Garattini S (eds): Amphetamines and Related Compounds. New York, Raven Press, 1970, pp 897–904.Google Scholar
  23. Harrie JR: Caffeine and headache. JAMA 213: 628, 1970.PubMedCrossRefGoogle Scholar
  24. Hirsch SR: Precipitation of antipsychotic drugs in interaction with coffee or tea. Lancet 2: 1130–1131, 1979.PubMedGoogle Scholar
  25. Hofmann A: The discovery of LSD and subsequent investigations on naturally occurring hallucinogens, in Ayd FJ, Blackwell B (eds): Discoveries in Biological Psychiatry. Philadelphia, Lippincott, 1970, pp 91–106.Google Scholar
  26. Hollender MH: Pathological intoxication—is there such an entity? J Clin Psychiatry 40: 424–426, 1979.PubMedGoogle Scholar
  27. Hollister LE: Phencyclidine (PCP) use: Current problems. Int Drug Ther News 14: 17–20, 1979.Google Scholar
  28. Innes IR, Nickerson M: Norepinephrine, epinephrine, and the sympathomimetic amines, in Goodman LS, Gilman A (eds): The Pharmacological Basis of Therapeutics. New York, Macmillan, 1975, pp 477–513.Google Scholar
  29. Jaffe JH: Drug addiction and drug abuse, in Goodman LS, Gilman A (eds): The Pharmacological Basis of Therapeutics. New York, Macmillan, 1975, pp 284–324.Google Scholar
  30. Jaffe JH, Martin WR: Narcotic analgesics and antagonists, in Goodman LS, Gilman A (eds): The Pharmacological Basis of Therapeutics. New York, Macmillan, 1975, pp 245–283.Google Scholar
  31. Janowsky DS, El-Yousef MK, Davis JM, et al: Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 28: 185–191, 1973.PubMedCrossRefGoogle Scholar
  32. Kolansky H, Moore WT: Toxic effects of chronic marihuana use. JAMA 222: 35–41, 1972.PubMedCrossRefGoogle Scholar
  33. Kolodny RC, Masters WH, Kolodner RM, et al: Depression of plasma testosterone levels after chronic intensive marihuana use. N Eng J Med 290: 872–874, 1974.CrossRefGoogle Scholar
  34. Kulhanek F, Linde OK, Meisenberg G: Precipitation of antipsychotic drugs in interaction with coffee or tea. Lancet 2: 1130, 1979.PubMedCrossRefGoogle Scholar
  35. Louria DB: Lysergic acid diethylamide. N Eng J Med 278: 435–438, 1968.CrossRefGoogle Scholar
  36. McManamy MC, Schube PG: Caffeine intoxication: Report of a case the symptoms of which amounted to a psychosis. N Eng J Med 215: 616–620, 1936.CrossRefGoogle Scholar
  37. Maugh TH: Marihuana: II. Does it damage the brain? Science 185: 775–776, 1974.PubMedCrossRefGoogle Scholar
  38. Mikkelsen EJ: Caffeine and schizophrenia. J Clin Psychiatry 39: 732–736, 1978.PubMedGoogle Scholar
  39. Morgan JP, Solomon JL: Phencyclidine: Clinical pharmacology and toxicity. NY State J Med 78: 2035–2038, 1978.Google Scholar
  40. Nahas GG: Marihuana: Toxicity, tolerance, and therapeutic efficacy. Drug Ther 4: 33–47, January 1974.Google Scholar
  41. Neil JF, Himmelhoch JM, Mallinger AG, et al: Caffeinism complicating hypersomnic depressive episodes. Comp Psychiatry 19: 377–385, 1978.CrossRefGoogle Scholar
  42. Petersen RC, Stillman RC: Phencyclidine: A review. Hosp Formul 14: 334–344, 1979.Google Scholar
  43. Pillard RC: Marihuana. N Eng J Med 283: 294–303, 1970.CrossRefGoogle Scholar
  44. Rada RT, Kellner R: Drug treatment in alcoholism, in Davis JM, Greenblatt D (eds): Psycho-pharmacology Update: New and Neglected Areas. New York, Grune & Stratton, 1979, pp 105–144.Google Scholar
  45. Rosenberg JM: Alcohol, your toughest prescribing problem. Curr Prescribing 1: 40–43, 1975.Google Scholar
  46. Schuckit MA: Drug and Alcohol Abuse. New York, Plenum Press, 1979.Google Scholar
  47. Seixas FA: Drug/alcohol interactions: Avert potential dangers. Geriatrics 34: 89–102, 1979.PubMedGoogle Scholar
  48. Showalter CV, Thornton WE: Clinical pharmacology of phencyclidine toxicity. Am J Psychiatry 134: 1234–1237, 1977.PubMedGoogle Scholar
  49. Siomopoulos V: Amphetamine psychosis: Overview and a hypothesis. Dis New Syst 36: 336–339, 1975.Google Scholar
  50. Sioris LJ, Krenzelok EP: Phencyclidine intoxication: A literature review. Am J Hosp Pharm 35: 1362–1367, 1978.PubMedGoogle Scholar
  51. Smith DE, Fischer CM: An analysis of 310 cases of acute high-dose methamphetamine toxicity in Haight-Ashbury. Clin Toxicol 3: 117–124, 1970.PubMedCrossRefGoogle Scholar
  52. Snyder SH: Amphetamine psychosis: A “model” schizophrenia mediated by catecholamines. Am J Psychiatry 130: 61–67, 1973.PubMedGoogle Scholar
  53. Stern SL, Rush AJ, Mendels J: Toward a rational pharmacotherapy of depression. Am J Psychiatry 137: 545–552, 1980.PubMedGoogle Scholar
  54. Streltzer J, Leigh H: Amphetamine abstinence psychosis—does it exist? Psychiat Opinion 14: 47–50, 1977.Google Scholar
  55. Tennant FS, Groesbeck CJ: Psychiatric effects of hashish. Arch Gen Psychiatry 27: 133–136, 1972.PubMedCrossRefGoogle Scholar
  56. Van Kammen DP, Murphy DL: Attenuation of the euphoriant and activating effects of d-and 1-amphetamine by lithium carbonate treatment. Psychopharmacologia 44: 215–224, 1975.PubMedCrossRefGoogle Scholar
  57. Victor M, Adams RD: Alcohol, in Isselbacher KJ, Adams RD, Braunwald E, et al (eds): Harrison’s Principles of Internal Medicine, ed 9. New York, McGraw–Hill, 1980a, 969–977.Google Scholar
  58. Victor M, Adams RD: Opiates and synthetic analgesics, in Isselbacher KJ, Adams RD, Braunwald E, et al (eds): Harrison’s Principles of Internal Medicine, ed 9. New York, McGraw–Hill, 1980b, pp 978–982.Google Scholar
  59. Weissman MM, Slobetz F, Prusoff B, et al: Clinical depression among narcotic addicts maintained on methadone in the community. Am J Psychiatry 133: 1434–1438, 1976.PubMedGoogle Scholar
  60. Wesson DR, Smith DE: Recognizing and treating amphetamine abuse. Hosp Physician 9: 22–26, August 1973.Google Scholar
  61. West AP: Interaction of low-dose amphetamine use with schizophrenia in outpatients: Three case reports. Am J Psychiatry 131: 321–323, 1974.PubMedGoogle Scholar
  62. Wharton RN, Perel JM, Dayton PG, et al: A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry 127: 1619–1625, 1971.PubMedGoogle Scholar
  63. Winstead DK: Coffee consumption among psychiatric inpatients. Am J. Psychiatry 133: 1447–1450, 1976.PubMedGoogle Scholar
  64. Young D, Scoville WB: Paranoid psychosis in narcolepsy and the possible danger of benzedrine treatment. Med Clin North Am 22: 637–646, 1938.Google Scholar

Copyright information

© Plenum Publishing Corporation 1981

Authors and Affiliations

  • James W. Jefferson
    • 1
  • John R. Marshall
    • 1
  1. 1.University of Wisconsin Medical SchoolMadisonUSA

Personalised recommendations